Public Health

The Deadliest Wildfire in Modern US History Is Teaching Us That the Fire Is Only Half the Harm

Nearly three years after flames destroyed Lāhainā and killed more than 100 people, the most striking finding from the study tracking survivors is not about smoke or burns. It is that much of the lasting damage came from what happened after the fire went out, from losing homes and jobs, and that this harm reached people who never lived near the flames.

That result is changing how researchers think about what disaster recovery actually needs to do.

What the study is

Once a month, University of Hawaiʻi researchers fly medical equipment from Oʻahu to west Maui and turn a local health center into a temporary lab, collecting blood, urine, DNA, lung function, and mental health measures from wildfire survivors. The Maui Wildfire Exposure Study, MauiWES, is one of the largest and most comprehensive postfire investigations in the country, designed to follow participants for a decade or more to see whether they develop cancers, lung disease, and other conditions linked to fire exposure.

What makes it scientifically valuable is who it enrolls. It is the largest and most ethnically diverse longitudinal cohort in any US postfire study, including Native Hawaiian, Pacific Islander, Hispanic, Filipino, Asian, and white residents, with 91% of participants having lived or worked in Lāhainā during the fire. That diversity matters because most of what is known about disaster health comes from less representative populations, and the communities hit hardest here were already facing health disparities and limited access to care before the fire.

The finding that reframes everything

The headline result, published in JAMA Psychiatry, is counterintuitive enough to change practice. The fires triggered an island-wide mental health crisis, and more than half of the disaster's impact on depression and anxiety could be traced to increased housing and job insecurity rather than to the trauma of the fire itself.

The numbers make the point precisely. People inside the burn zones had a 53% higher risk of depression and a 67% higher risk of anxiety. But for wildfire survivors, housing and job insecurity explained nearly 62% of the depressive symptoms and 77% of the anxiety symptoms the disaster caused. And the harm did not respect the edge of the burn zone. Maui residents who lived outside the fire areas also showed significantly elevated risks, including more than double the risk of suicidal thoughts.

Sit with what that means. The thing most damaging to mental health was not proximity to the flames. It was losing your home and your income, which can happen to someone whose house never burned, in a place where the fire destroyed so much housing and economic activity that the disruption rippled across the whole island. As the study's lead author put it, housing displacement and income loss were not side issues but central drivers of psychological harm.

One corollary from the same data points straight at a solution: being employed was strongly protective against depression, anxiety, and suicidal thoughts. That is not a soft observation. It says that economic recovery is mental health treatment, that getting people back into stable housing and work does clinical good that is otherwise hard to achieve.

Why this changes the recovery playbook

The conventional model of disaster response treats the acute event as the emergency: put out the fire, treat the injured, provide short-term shelter, then wind down as the crisis passes. This study is evidence that the model ends too early and aims at the wrong target.

If most of the lasting psychological harm flows from housing and job loss, then the recovery that actually protects health is not measured in weeks of emergency response. It is measured in how fast people get back into permanent homes and stable work, which in Lāhainā has been painfully slow, with fewer than 300 homes rebuilt as of this summer against thousands destroyed and roughly 10,000 people displaced. Every month of delayed rebuilding is not just a housing problem. On this evidence, it is an active mental health harm, prolonging the exposure that drives the depression and anxiety.

That reframing has a practical edge. It means the agencies responsible for housing, permitting, and economic recovery are, functionally, mental health agencies after a disaster, whether or not anyone describes them that way. And it means a recovery judged successful on physical rebuilding metrics can still be failing on the measure that matters most to survivors, if it leaves people in limbo for years.

The physical health signals are real too

The mental health findings are the most developed, but the study is also tracking bodies, and the early readings warrant the long timeline. Among adults enrolled six to 14 months after the fires, 22% showed reduced lung function and 50% screened positive for depressive symptoms. Later reporting from the study found more than 40% of adults reporting worsening health, nearly 75% with elevated blood pressure, and more than a quarter with worsening lung function, alongside more than half of children aged 8 to 18 screening positive for depression.

These are screening findings from an exposed cohort, not proof that the fire caused each condition, and the study is careful about that distinction, which is exactly why it is designed to run for a decade or two. Urban wildfires like Lāhainā burn homes, cars, plastics, and industrial materials, producing a chemical mix quite different from a forest fire, and the long-term consequences of breathing that are genuinely not well understood. The value of following the same people for years is that it can separate lasting effects from transient ones in a way a snapshot never could.

The part that makes this fragile

There is a hard irony in the timing. This study exists to show that long-term support matters, and its own long-term funding is uncertain. Hawaiʻi cut state funding for the study earlier this year, with a $3 million request described as crucial to continue screenings, return results, provide referrals, and expand care to a waitlist that includes 1,000 children. NIH has renewed a portion of the funding, but the gap between what the study needs and what it has is real.

That threatens something beyond the research. For many participants, MauiWES is not only a study; it is a source of actual screening and referral in a community with limited access to care, the mechanism by which someone learns their lung function has declined or their blood pressure is dangerous. Defunding it removes both the knowledge and, for some, the care.

A study researcher drew a comparison worth taking seriously, to September 11, where in the years afterward more people died from illnesses linked to the exposure than in the attack itself, and where a long-term health program eventually became essential precisely because the delayed harms were not visible at first. The parallel is a warning: the costs that show up later are easy to underfund now, exactly because they have not shown up yet. Investing in prevention and monitoring is cheaper than treating the crises that arrive when no one was watching, but only if the monitoring survives long enough to do its job.

Lāhainā is teaching a lesson that applies well beyond Maui, as wildfires grow more frequent and more likely to reach towns rather than just wildland. The fire is the visible disaster. The invisible one is the slow grind of displacement, lost income, and prolonged instability, and on this evidence that second disaster does more lasting damage to mental health than the first. The most important finding of the largest postfire study in the country is almost administrative in its plainness: what you do in the years after the fire matters as much as the fire, and the recovery is not over when the emergency ends. It is over when people are home.

If you or someone you know is struggling in the aftermath of a disaster or experiencing thoughts of suicide, support is available. In the US, the 988 Suicide and Crisis Lifeline can be reached by calling or texting 988.

Further reading

Written by James T.

Do you disagree with any of the medical statements in this article? Email medical_disputes@mavengity.com with your feedback.

This is general information about a research study and disaster recovery, not medical or mental health advice. Screening findings from a study cohort do not establish causation for any individual. Anyone concerned about their physical or mental health after a disaster should consult a qualified clinician. Sources: STAT, Honolulu Civil Beat, Science/AAAS, JAMA Network Open, and AsAmNews. Mavengity is editorially independent.
Keep reading

More from Healthcare & Medical

Biotech Workforce

Boston Mastered Biotech's First Era. One Founder's Move to California Is a Question About Its Second

A Harvard-and-MIT-trained founder who fits Boston's exact entrepreneurial profile built his biotech company in California instead. One anecdote isn't a migration, but it points at a real risk, the source of biotech's regional advantage may be shifting from wet-lab biology to computation.

By James T.·8 min read
Public Health

One Year After the CDC Shooting, the Danger to Public Health Has Shifted From the Diseases It Fights to the Trust It Needs

A year after a gunman fired more than 180 rounds at CDC headquarters, killing a police officer, staff say they still feel targeted. The deepest damage wasn't the shattered windows, it was to the trust public health depends on to function at all.

By James T.·9 min read
Science Policy

The NIH Plans to Bar Visa-Holding Scientists From a Career-Making Grant. The Real Cost Is Retention, and It's Easy to Miss

The NIH plans to close its K99/R00 "Pathway to Independence" award to scientists on temporary visas, removing one of the few federal bridges from postdoc to independent faculty for international researchers. The policy has a real case behind it, and a cost that is real, delayed, and easy to miss.

By James T.·9 min read
Clinical Trials

The FDA Cleared a Melanoma Drug It Twice Rejected. The Approval Defers the Hard Question to a Trial Still Running

The FDA accelerated-approved Replimune's RP1 for advanced melanoma after two rejections and a contentious 10-3 advisory vote. The approval does not resolve whether RP1 itself drives the durable survival benefit seen in its single-arm trial, that question now falls to a confirmatory trial years from reporting.

By James T.·8 min read
Medicare Policy

A Relabeling Meant to Invite Competition Gave an Old AbbVie Drug Seven More Years Before Price Negotiation

A Public Citizen report says CMS treated AbbVie's decades-old Creon as freshly protected biologic innovation after a purely administrative reclassification, delaying Medicare price negotiation by seven years on a drug that cost the program $1.49 billion in 2024.

By James T.·9 min read
Medical News

Tau May Harm Neurons by Running Their Mitochondria in Reverse. That's a Genuine New Lead, and a Familiar Long Shot

A Stanford-led study found that tau can drive electrons backward through neurons' mitochondria, generating the oxidative stress that damages them. The mechanism is specific and genuinely new, but it still faces the same distance from animal models to human treatment that has humbled nearly every Alzheimer's lead before it.

By James T.·9 min read
Health Policy

A Closed-Door Clinical-AI Demo Day With Regulators Shows Why Industry Engagement Is Both Necessary and Risky

Federal health officials held an unannounced, closed-door demo day with ten clinical-AI companies at FDA headquarters. The episode captures a real tension, regulators need to understand fast-moving technology firsthand, but private, selective access is the classic setup for regulatory capture.

By James T.·9 min read
Public Health

Erica Schwartz Is Confirmed to Lead the CDC, on the Strength of What She Declined to Promise

The Senate confirmed Dr. Erica Schwartz to lead the CDC after she declined to say whether she would defend the agency's science against political pressure. That evasiveness was not a flaw in her candidacy, it was the mechanism that made her confirmable.

By James T.·7 min read
Medicare Policy

The Orphan-Drug Exemption Was Built for Small Markets. It Now Protects Blockbusters, Which Is Why It Guts Medicare's Savings

A new analysis finds that exempting orphan drugs from Medicare's drug-pricing pilots would erase most of their savings. The paradox unwinds once you see that the orphan label, meant for tiny markets, now also covers blockbusters like Keytruda.

By James T.·9 min read
Medical Screening

In Prostate Cancer, a Better Test Finds Fewer Cancers. The MRI-Versus-Biopsy Debate Is Really About Overdiagnosis

Prostate cancer is extremely common and rarely deadly, a combination partly explained by overdiagnosis. Growing trial evidence favors MRI-first diagnosis over systematic biopsy precisely because it finds less indolent cancer, not more.

By James T.·10 min read
Clinical Trials

Prehabilitation for Frail Heart-Transplant Candidates Reframes Eligibility as a Movable Threshold, Not a Fixed Trait

A new in-patient exercise program helped previously ineligible, hospitalized heart-transplant candidates qualify for surgery. It reveals that frailty-based ineligibility is often a gap in the care pathway rather than a fixed fact about the patient, and it raises a hard question about a scarce resource.

By James T.·9 min read
Medicare Policy

Medicare Is Tightening Breakthrough-Device Payments and Speeding Their Coverage. Understanding the Difference Explains the Policy.

CMS finalized a rule eliminating shortcuts that let FDA breakthrough-designated devices skip proof of clinical improvement to earn extra Medicare payments. A separate move speeds coverage instead. Read as a package, it's a deliberate rebalancing, not a simple cut.

By James T.·9 min read
Public Health

The 2026 Cyclospora Outbreak Records Its First Deaths, and Its Source, Scale, and Danger Are Each Less Simple Than They Appear

Michigan reported the first two U.S. deaths in a cyclospora surge with over 18,000 cases nationally. The source is not one contamination event, the count is both undercounted and unevenly tallied, and the danger concentrates in a vulnerable subgroup the "usually mild" description hides.

By James T.·8 min read
Science Policy

A Senate Bill Blocks Political Control of Research Grants. The Real Question Isn't Whether Politics Belongs, but Where.

A bipartisan Senate funding bill would temporarily block a White House proposal giving political appointees control over individual federal research grants. The real fight is about which level of the decision political accountability should reach, not whether it belongs at all.

By James T.·9 min read
Clinical Trials

The FDA's Advisers Backed a Drug They Couldn't Fully Interpret and Rejected One They Called a "Mirage." The Difference Is Trust.

Two FDA advisory committees faced imperfect evidence for two drugs in the same week and split in opposite directions. The deciding factor wasn't how much proof each had, but whether the proof could be believed.

By James T.·8 min read
Public Health

Syphilis Is Curable With a Cheap, 80-Year-Old Shot. Every Reason It's Spreading Is a System Failure.

A single injection has cured syphilis for eighty years, yet congenital syphilis rates have risen more than 200% in five years. A national penicillin shortage, no substitute drug for pregnant patients, and gaps in surveillance explain why, not any failure of the medicine itself.

By James T.·9 min read
Science Policy

A Diabetes Group Fought for Editorial Independence in 2015. Now It's Suppressing Its Own. The Difference Is Who It Costs.

The American Diabetes Association defended a journal's editorial independence in 2015 when it was cheap. In 2026 it suppressed its own researchers when defending them risked its NIH funding relationship. The contrast reveals when institutional principle actually holds.

By James T.·9 min read
Pharma Regulation

The FDA Halted Every Trial Using One Vector and Restored Only One. The Inconsistency Is More Defensible Than It Looks.

The FDA paused all of Sarepta's LGMD gene-therapy trials after deaths tied to a shared viral vector, then restored access disease by disease. The pattern looks inconsistent but reflects a real difference in how safety and benefit evidence behave.

By James T.·9 min read
Clinical Trials

Novo Nordisk's Drug Lowered Inflammation Perfectly. It Prevented Zero Heart Attacks. That Gap Is Why Outcomes Trials Exist.

Novo's ziltivekimab hit its inflammation targets precisely in a 6,300-patient trial but produced no reduction in heart attacks, strokes, or cardiovascular deaths. The gap between a moved surrogate and an unmoved outcome is the whole lesson.

By James T.·8 min read
Health Policy

The Agency That Studies How American Health Care Actually Works Just Lost $109 Million in Research

AHRQ stopped funding dozens of health services studies mid-stream. The mechanism matters as much as the money.

By James T.·8 min read
Health Tech

Radiologists Have Been Using AI for Years. Now It's Learning to Write.

The FDA just granted Breakthrough Device status to two AI systems that draft chest X-ray reports, not just flag abnormalities on them.

By James T.·8 min read
Revenue Cycle AI

"Capture the Full Patient Story" Is the Most Consequential Phrase in Health Tech Right Now

Generative AI that finds missed documentation and AI that maximizes billing intensity are the same product, distinguishable only by whether the facts support the code.

By James T.·7 min read
Gene Editing

The Miracle That Doesn't Scale

ARPA-H just put $160 million behind custom gene editing, inspired by the baby who was saved by it.

By James T.·8 min read
Pharma AI

Three Drugmakers Have Announced Pharma's "Largest" AI Supercomputer in Nine Months

Bristol Myers Squibb's claim contains four qualifiers. What's verifiable, and more interesting, is a 55% cost reduction and a specific bet about where compute helps.

By James T.·8 min read
Medical News

The Most Measured Man Alive Missed It for Ten Years

Bryan Johnson spends a fortune tracking his own biology. An autoimmune disease still hid inside him for a decade.

By James T.·9 min read
Public Health

Congress Rejected the HIV Prevention Cuts in January. The Money Still Isn't Going Out.

Lawmakers preserved $1.384 billion in CDC prevention funding. Six months later, OMB declined to renew $46 million for a prevention program anyway.

By James T.·7 min read
Gene Editing

The Hard Part of Curing Rare Diseases Is No Longer the Science

A new nonprofit is built on the premise that gene editing already works, and the reason so few children get it is that every therapy is built from scratch.

By James T.·7 min read
Medicare Policy

Medicare's 2027 Physician Pay Cut Isn't a Cut. It's a Patch Expiring, and a Permanent Fork Opening.

The decline comes entirely from a one-year congressional increase lapsing, while a separate two-track payment structure quietly widens every year, forever.

By James T.·8 min read
Bundled Payments

Medicare's New Mandatory Surgery Bundle Puts Hospitals at Risk for What Happens After Discharge

For most TEAM procedures, post-acute care is a minor cost. For hip fracture patients, the frailest in the model, it's 54%.

By James T.·8 min read
Public Health

The Lettuce Never Tested Positive. The Recall Is Still Right.

FDA's one positive Cyclospora sample was a false positive. The recall stands anyway, because outbreak investigations run on epidemiology, not lab results.

By James T.·8 min read
Medicaid Policy

Family Caregivers Face Ruin as States Cut Medicaid Wages

Several states want to slash the pay of parents and relatives who care for people with disabilities, ahead of a $1 trillion federal Medicaid cut.

By James T.·7 min read
Health Tech

Hospitals Are Starting to Subscribe to Their Medical Equipment Instead of Buying It

GE HealthCare's $500 million, 10-year deal with Catholic Health turns capital equipment into something closer to a subscription.

By James T.·7 min read
Healthcare M&A

Private Equity Used to Outbid Hospitals for Medical Practices. In 2026 That Flipped.

PE deal volume hit a five-year high while its valuations collapsed from 15.3x to 10.7x, and strategic buyers now pay more.

By James T.·8 min read
Health Tech

Hospitals Are Governing AI With a Process Designed for MRI Machines. The Mismatch Is the Danger.

Most hospitals oversee clinical AI with a review process built for a technology that doesn't update itself monthly.

By James T.·8 min read
Medical Devices

A Surgical Robot Company Just Gave Us the Clearest Evidence Yet That People Are Skipping Care

Intuitive Surgical beat earnings and its stock fell anyway, because US procedure growth slowed as ACA subsidies lapsed.

By James T.·7 min read
Health Insurance

23 Million Americans Are Staying in Jobs They Want to Leave. The System Is Working as Designed.

Job lock isn't a malfunction. It's employer-based insurance doing exactly what it was built to do.

By James T.·8 min read
Pharma Access

The First Cholesterol Pill of Its Kind Just Won Approval. Whether It Reaches Patients Is a Separate Question.

Merck's Lipfendra matches injectable PCSK9 inhibitors. The injectable versions already showed that a drug can work and still fail to reach patients.

By James T.·8 min read
Clinical Data

Doctors Use 800 Clinical Calculators Daily. Some Were Built on Studies of Five People.

MDCalc is launching quality ratings for the clinical tools millions of physicians consult, scoring validation, usability, and embedded bias.

By James T.·7 min read
Medicaid Policy

The Medicaid Fight Isn't Really About $1 Billion. It's About When the Government Gets to Hold the Money.

HHS deferred over $1 billion in Medicaid payments pending fraud documentation. The procedural question underneath will outlast this dispute.

By James T.·8 min read
Medicare Policy

Medicare Pays About $10 for a Conversation That Could Add Years to Someone's Life

A proposed 19.1% increase would raise tobacco cessation counseling to roughly $12. That's the right direction, and probably not enough to change the arithmetic.

By James T.·7 min read
Medical Screening

The Pentagon Will Screen Troops for Low Testosterone. Screening and Diagnosing Are Not the Same Thing.

Guidelines recommend treatment only for confirmed deficiency and symptoms. Screening finds asymptomatic cases, in an occupation that lowers testosterone by design.

By James T.·8 min read
Health Policy

Nevada's Governor Race Turns on Health Care Costs. How Much Can a Governor Actually Control?

Joe Lombardo and Aaron Ford are both promising to fix health care affordability. Here's what a Nevada governor can and cannot actually control.

By James T.·8 min read
Hospital Finance

Nonprofit Hospitals Hold $300 Billion in Investments. They're Moving It Into Assets They Can't Sell Quickly.

Portfolios are shifting into private equity and hedge funds, exactly the assets that lock up when markets seize, while investment income is nearly half of net income.

By James T.·8 min read
Health Policy

Orphan Drug Status Has Become the Most Valuable Regulatory Designation in Pharma

Rare disease companies keep winning pricing exemptions. Each carve-out is defensible. Together they are redirecting where the industry spends its research money.

By James T.·8 min read
Public Health

Pandemic Preparedness Is Already Being Treated as National Security. That Framing Funds Some Things and Starves Others.

Securitization reliably funds countermeasures and detection. It reliably does not fund the public health capacity that determined how Covid actually went.

By James T.·9 min read
Medical Devices

A Device Just Restored Reading Vision to Blind Patients. Americans Will Wait Years for It.

A retinal chip restored reading vision to macular degeneration patients in Europe. The US gap is wider than the coverage suggests.

By James T.·8 min read
Medical Screening

The FDA Made Two Changes to Testosterone Labels. Only One Was Backed by New Evidence.

One removed a disproven prostate cancer warning. The other removed a statement that benefits were unproven in older men, which no new evidence overturned.

By James T.·8 min read
Health Insurance

UnitedHealth's Profits Jumped While It Lost 525,000 Members. Those Facts Are Connected.

The CFO said the margin gain wasn't from costs coming under control, it was from exiting members and plans priced below cost.

By James T.·8 min read
Public Health

As Infectious Threats Reappear, U.S. Public-Health Cuts Face a Real-World Test

Federal agencies say essential disease monitoring remains intact. Specialists warn that reduced staffing could make emerging threats harder to detect.

By James T.·10 min read
Public Health

The Air You Breathe and the Air the Law Recognizes Are Drifting Apart

A Clean Air Act provision lets states delete wildfire smoke readings from compliance records. Fifty EPA monitors hit hazardous levels in a single day this month.

By James T.·8 min read
Public Health

A Nation's Team Losing on Penalties Is One of the Few Heart-Attack Spikes You Can See Coming

Hospitals record measurable cardiac spikes timed to World Cup matches. The surge is predictable, and mostly unplanned for.

By James T.·8 min read
Medicaid Policy

Medicaid's New Exemption Is for People Too Sick to Work. Claiming It Requires the Very Capacity Being That Sick Takes Away.

CMS's medically-frail exemption from Medicaid work requirements now demands proof of functional incapacity, a documentation burden that falls hardest on the sickest enrollees it is meant to protect.

By James T.·10 min read
Pharma Supply Chain

Is America's Drug-Supply Vulnerability China's Fault or Our Own? The Answer Is Both, and the Order Matters.

A market-failure argument and a national-security argument about pharmaceutical dependence on China are not rivals, they answer different questions, cause and stakes, and both have to be fixed together for either fix to hold.

By James T.·9 min read
Pharma Supply Chain

Oil Shocks Make Some Medicines Pricier. The Weak Point Isn't Shipping, It's the Chemistry Itself.

A Unitaid analysis of a widely used HIV treatment finds that over 85% of oil-driven cost increases come from upstream petrochemical feedstocks and solvents, not transport, relocating a risk most supply-chain fixes do not address.

By James T.·9 min read
Medicaid Policy

A Judge Declined to Pause Medicaid's New Work Rule. He Didn't Decide Whether It's Lawful, and That Distinction Is the Whole Story.

A federal judge denied a preliminary injunction against Medicaid's new work-requirement rule on procedural grounds, not on the merits, and the reasoning exposes a structural timing gap in how these legal challenges work.

By James T.·8 min read
Health Policy

Cassidy Traded His Vote for Assurances Once Before. Those Reportedly Broke. He Just Did It Again.

Senator Bill Cassidy cast a decisive committee vote for a vaccine-skeptic HHS nominee after securing private, unenforceable assurances, the same trade he made for RFK Jr., whose promises reportedly were not kept.

By James T.·8 min read